Conference Roundup

Positive results from Phase 2 trial of ABBV-RGX-314 for diabetic retinopathy presented at AAO 2023

Positive results from the ongoing Phase 2 ALTITUDE trial of ABBV-RGX-314, a potential one-time gene therapy for the treatment of diabetic retinopathy (DR) without center-involved diabetic macular edema (CI-DME), were reported at AAO 2023. The trial showed promising outcomes in terms of safety and efficacy, including stability and improvement in...